Rare Metabolic Disorder
It is distinguished by elevated levels of the amino acid valine in the blood and urine caused by deficit of the enzyme valine transaminase. This enzyme is needed in the breakdown of valine, this condition is called as Valinemia which is a very rare metabolic disorder.
Related Conference of Rare Metabolic Disorder
September 24-25, 2026
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
Paris, France
November 16-17, 2026
19th International Conference on Human Genomics and Genomic Medicine
Tokyo, Japan
Rare Metabolic Disorder Conference Speakers
Recommended Sessions
- Analytical techniques
- Cancer metabolism
- Carbohydrates in metabolism
- Exometabolomics
- Immuno Metabolomics
- Lipids metabolism
- Mass spectroscopy based metabolomics
- Metabolic Fingerprinting
- Metabolic Pathways
- Metabolic Profiling
- Metabolic syndrome
- Metabolism
- Metabolism Syndrome Treatments
- Metabolites
- Metabolome
- Metabolomics
- Metabolomics Approaches
- Metabolomics in various Diseases
- Metabonomics
- Minerals and vitamins in metabolism
- NMR Spectroscopy Based Metabolomics
- Plant Metabolomics
- Proteins Metabolism
- Rare Metabolic Disorder
Related Journals
Are you interested in
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)